Fat Overload in Joint Cartilage Drives Arthritis by Destroying a Key Protective Protein

Osteoarthritis (OA) affects hundreds of millions worldwide and is strongly associated with obesity, yet the precise metabolic mechanisms linking excess fat to cartilage destruction have remained poorly understood. This study from Zhejiang University provides a detailed molecular account of how fatty acid overload in chondrocytes—the cells that maintain cartilage—drives OA progression through two interconnected pathways: SOX9 protein degradation and epigenetic dysregulation.

Using a combination of cell culture, mouse models, and human cartilage samples, the researchers first established that free fatty acids (FFAs) accumulate in osteoarthritic cartilage early in disease, before histological changes appear. They showed that adipocyte-derived FFAs, not adipokines, are the primary drivers of cartilage ECM breakdown in vitro. Inflammatory cytokines (IL-1β, TNF-α) and mechanical stress synergistically enhanced fatty acid uptake in chondrocytes by upregulating transporters like CD36, FATP5, and FABP3. A high-fat diet combined with surgical joint destabilization (HFD-DMM mouse model) recapitulated human obesity-associated post-traumatic OA, with lipidomic profiling confirming massive increases in long-chain saturated and unsaturated FFAs in cartilage.

Mechanistically, elevated FAO in chondrocytes caused acetyl-CoA accumulation. This shifted the global protein acetylation landscape, with the core FAO enzyme HADHA becoming hyperacetylated at lysine 406—a modification that increased its activity, creating a destructive positive-feedback loop that further amplified FAO and acetyl-CoA production. Critically, elevated FAO suppressed AMPK activity. AMPK normally phosphorylates SOX9 at serine 181, protecting it from ubiquitin-mediated proteasomal degradation. With AMPK impaired, SOX9 phosphorylation dropped, ubiquitination increased (mediated by RNF4 and CHIP E3 ligases), and SOX9 protein levels collapsed—abolishing its protective transcriptional program for cartilage matrix genes COL2A1 and ACAN.

Additionally, the acetyl-CoA surplus drove histone acetylation changes, particularly H3K27ac enrichment at the promoters of MMP13 and ADAMTS7, transcriptionally activating these catabolic enzymes and further degrading cartilage ECM. RNA-seq and CUT&Tag chromatin profiling confirmed broad epigenetic reprogramming in FFA-treated chondrocytes consistent with OA pathogenesis.

Therapeutically, the researchers used cartilage-targeted polymeric nanoparticles to deliver trimetazidine—an FAO inhibitor used clinically for cardiac ischemia that also activates AMPK—directly into joints of HFD-DMM mice. Intra-articular injection of trimetazidine nanoparticles outperformed free drug and significantly reduced cartilage degradation scores, restored SOX9 levels, and suppressed catabolic marker expression. These findings position chondrocyte lipid metabolism as a tractable therapeutic target and suggest repurposing FAO inhibitors for OA treatment, particularly in metabolically compromised patients.